Drugs / APX-343A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07123415 | Oct 2025 → Oct 2028 expected | cancer | Aptabio Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APX-343A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07123415 ↗ |
| Route | Oral | “Oral administration twice daily” NCT07123415 ↗ |